Eichenauer DA - Search Results

1

Controversies in the Treatment of Classical Hodgkin Lymphoma.

Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A. Eichenauer DA, et al. Hemasphere. 2018 Oct;2(5):e149. doi: 10.1097/HS9.0000000000000149. Epub 2018 Oct 2. Hemasphere. 2018. PMID: 30887012 Free PMC article. Review.

2

ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.

Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. Eichenauer DA, et al. Cancer Res. 2007 Jan 1;67(1):332-8. doi: 10.1158/0008-5472.CAN-06-2470. Cancer Res. 2007. PMID: 17210715

3

Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Engert A, et al. Among authors: eichenauer da. Ann Oncol. 2009 May;20 Suppl 4:108-9. doi: 10.1093/annonc/mdp144. Ann Oncol. 2009. PMID: 19454425 Review. No abstract available.

4

Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?

Eichenauer DA, Engert A. Eichenauer DA, et al. Leuk Lymphoma. 2009 Nov;50(11):1733-4. doi: 10.3109/10428190903308098. Leuk Lymphoma. 2009. PMID: 19883301 No abstract available.

5

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.

Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Böll B, Chalaris A, Simhadri VR, Wiegmann K, Krell HW, Rose-John S, Engert A, von Strandmann EP, Hansen HP. Vahdat AM, et al. Among authors: eichenauer da. Leukemia. 2010 Jan;24(1):51-7. doi: 10.1038/leu.2009.230. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890373

6

Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.

Eichenauer DA, Bredenfeld H, Haverkamp H, Müller H, Franklin J, Fuchs M, Borchmann P, Müller-Hermelink HK, Eich HT, Müller RP, Diehl V, Engert A. Eichenauer DA, et al. J Clin Oncol. 2009 Dec 20;27(36):6079-85. doi: 10.1200/JCO.2008.20.2655. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901121

7

Nodular lymphocyte-predominant Hodgkin lymphoma.

Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A; German Hodgkin Study Group. Fuchs M, et al. Among authors: eichenauer da. Curr Hematol Malig Rep. 2008 Jul;3(3):126-31. doi: 10.1007/s11899-008-0019-5. Curr Hematol Malig Rep. 2008. PMID: 20425457

8

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).

Halbsguth TV, Nogová L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A. Halbsguth TV, et al. Among authors: eichenauer da. Blood. 2010 Sep 23;116(12):2026-32. doi: 10.1182/blood-2009-11-253211. Epub 2010 Jun 15. Blood. 2010. PMID: 20551376 Free article. Clinical Trial.

9

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Engert A, et al. Among authors: eichenauer da. Ann Oncol. 2010 May;21 Suppl 5:v168-71. doi: 10.1093/annonc/mdq181. Ann Oncol. 2010. PMID: 20555072 Free article. No abstract available.

10

Expanded use of rituximab in the management of non-Hodgkin lymphoma.

Eichenauer DA, Engert A, Schulz H. Eichenauer DA, et al. Onco Targets Ther. 2009 Feb 18;2:189-97. doi: 10.2147/ott.s3322. Onco Targets Ther. 2009. PMID: 20616906 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

123 results

Search Page